The enhancement of T cell proliferation by L-dopa is mediated peripherally and does not involve interleukin-2

Journal of Neuroimmunology

Volumn 142, Issue 1-2, 2003, Pages 166-169

  Carr, Laurence ^a   Tucker, Alison ^a   Fernandez Botran, Rafael ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Dopamine; Interleukin 2; Proliferation; T lymphocytes

Indexed keywords

CONCANAVALIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEVODOPA; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIVISION; CELLS, CULTURED; CONCANAVALIN A; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LEVODOPA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES;

EID: 0642340365     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00270-4     Document Type: Article

References (22)

1. 2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J. Auton. Pharm. 19:1999;151-159.
2. Basu S., Dasgupta P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102:2000;113-124.
3. Basu S., Banerjee S., Dasgupta P.S., Roychowdhury J. Stimulation of splenic lymphocyte proliferation and increased life span of solid Ehrlich carcinoma-bearing mice following dopamine treatment. Biog. Amines. 9:1992;171-181.
4. Basu S., Dasgupta P.S., Lahiri T., Roychowdhury J. Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci. 53:1993;415-424.
5. Bencsics A., Serchen H., Baranyi M., Hashim A., Lajtha A., Vizi E.S. Dopamine, as well as norepinephrine, is a link between noradrenergic nerve terminals and splenocytes. Brain Res. 761:1997;236-243.
6. Bergquist J., Tarkowski A., Ekman R., Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl. Acad. Sci. USA. 91:1994;12912-12916.
7. Bianchine J.R., Calimlin L.R., Morgan J., Dujovne C., Lasagna L. Metabolism and absorption of L-3,4-dihydroxy-phenylalanine in patients with Parkinson's disease. Ann. N.Y. Acad. Sci. 179:1971;126-140.
8. Boukhris W., Kouassi E., Descotes J., Cordier G., Revillard J.P. Impaired T-dependent immune response in L-dopa treated BALB/c mice. J. Clin. Lab. Immunol. 23:1987;185-189.
9. Calne D., Karoum F., Ruthven C., Sandler M. The metabolism of orally administered L-DOPA in parkinsonism. Br. J. Pharmacol. 37:1969;57-68.
10. Caronti B., Calderaro C., Passarelli F., Palladini G., Pontieri F.E. Dopamine receptor mRNAs in the rat lymphocytes. Life Sci. 62:1998;1919-1925.
11. Carr L., Tucker A., Fernandez-Botran R. In vivo administration of L-dopa or dopamine decreases the number of splenic IFNγ-producing cells. J. Neuroimmunol. 137:2003;87-93.
12. Cook-Mills J.M., Cohen R.L., Perlman R.L., Chambers D.A. Inhibition of lymphocyte activation by catecholamines: evidence for a nonclassical mechanism of catecholamine action. Immunology. 85:1995;5454-5549.
13. Fernandez-Botran R., Chilton P.M., Ma Y., Windsor J.L., Street N.E. The production of soluble interleukin 4 receptors is preferentially regulated by the murine Th2 subset. Cytokine. 9:1997;166-177.
14. Hanisch U.K., Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 21:1996;246-284.
15. Josefsson E., Bergquist J., Ekman R., Tarkowski A. Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology. 88:1996;140-146.
16. Kluter H., Vieregge P., Stolze H., Kirchner H. Defective production of interleukin-2 in patients with idiopathic Parkinson's disease. J. Neurol. Sci. 133:1995;134-139.
17. Kouassi E., Boukhris W., Descotes J., Zukervar P., Li Y.S., Revillard J.P. Selective T cell defects induced by dopamine administration in mice. Immunopharmacol. Immunotoxicol. 9:1987;477-488.
18. Neveu P.J., Deleplanque B., Vitello S., Rouge-Pont F., Le Moal M. Hemispheric asymmetry in the effects of substantia nigra lesioning on lymphocyte reactivity in mice. Int. J. Neurosci. 64:1992;1-4.
19. 1 receptors in the limbic system in the control of immune mechanisms. Neuroimmunomodulation. 1:1994;174-180.
20. Ricci A., Amenta F. Dopamine D5 receptors in human peripheral blood lymphocytes: a radio-ligand binding study. J. Neuroimmunol. 53:1994;1-7.
21. Tsao C.W., Lin Y.S., Cheng J.T. Effect of dopamine on immune cell proliferation in mice. Life Sci. 61:1997;PL 361-PL 371.
22. Wandinger K.P., Hagenah J.M., Kluter H., Rothermundt M., Peters M., Vieregge P. Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease. J. Neuroimmunol. 98:1999;214-220.